Germany first in EU to get Novartis’ SMA gene therapy, costing almost 2m euros
AveXis, gene therapy, market access, Novartis, SMA, ultra-rare diseases
0 Comment
AveXis
Novartis offers reimbursement options as EU backs costly SMA therapy
AveXis, Biogen, neurology, Novartis, Rare diseases, Roche, SMA, Zolgensma
0 Comment
Novartis closes on EU approval for SMA gene therapy Zolgensma
AveXis, CHMP, ema, gene therapy, Novartis, spinal muscular atrophy, Zolgensma
0 Comment
AveXis rules out EU compassionate use of SMA gene therapy, says Biogen option is available
AveXis, Novartis, Rare diseases, regulation, spinal muscular atrophy
0 Comment
Weekly roundup: More questions for Novartis in Zolgensma scandal
AveXis, fda, Novartis, spinal muscular atrophy, Zolgensma
0 Comment
PTC shares soar after SMA drug data impresses market
AveXis, Biogen, Novartis, PTC Therapeutics, SMA, spinal muscular atrophy, Spinraza
0 Comment
AveXis surges on promising gene therapy
AveXis, gene therapy
0 Comment
Company will discuss next steps with FDA shortly